Non-Small Cell Lung Cancer
Advertisement
A study detailed the landscape of lung adenocarcinoma progression.
MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.
Positive trial results and FDA approvals have changed the standard of care for NSCLC.
Preoperative ctDNA has prognostic value for determining long-term prognosis for NSCLC.
Clinical trial investigators should use a mindful approach when planning to assess HRQOL in NSCLC.
It is reasonable to upgrade ECE of tumor in lymph nodes from R0 to incomplete resection.
Worse clinical outcomes and higher risk for brain metastasis are more likely to happen in patients with metastatic NSCLC.
The use of tobacco negatively affects survival outcomes in patients with advanced NSCLC.
Patients with EGFR-positive metastatic NSCLC whose disease progressed following first-line treatment have worse outcomes.
Patient selection for perioperative immunotherapies may be determined by specific intratumoral immune cells.
A study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as neoadjuvant treatment.
The VISION study that evaluated pre/post-tepotinib treatment in advanced/metastatic METex14 skipping NSCLC.
Arun Krishna, of AstraZeneca, talks about the phase 3 FLAURA2 trial, which assessed Tagrisso in patients with NSCLC.
Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.
A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC.
Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control.
Researchers created a novel prediction model that can forecast OS in patients with adenocarcinoma.
Black and/or socioeconomically disadvantaged patients with advanced NSCLC have higher mortality rates.
A greater understanding of patients with HER2-mutated NSCLC is critical for developing therapies.
Although most of patients with NSCLC will receive immunotherapy, a growing percentage are eligible for targeted agents.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.